Literature DB >> 24777249

Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression.

Hirotake Tsukamoto1, Ryutaro Nishikata, Satoru Senju, Yasuharu Nishimura.   

Abstract

Collaborative action between tumor cells and host-derived suppressor cells leads to peripheral tolerance of T cells to tumor antigens. Here, we showed that in tumor-bearing mice, generation of tumor antigen-specific effector T-helper cells (TH1) was significantly attenuated, and impaired TH1 differentiation was restored by the temporal blockade of interleukin (IL)-6 activity at the T-cell priming phase. Furthermore, we found that Gr-1(+) myeloid-derived suppressor cells (MDSC) served as a source of IL-6 in tumor-bearing mice. Adoptive transfer of effector CD4(+) T cells revealed that MDSC-sensitized effector CD4(+) T cells were less potent in mounting antitumor immune responses, although effector T cells generated together with Gr-1(+) cells from tumor-free mice eradicated established tumors. CD8(+) T cells, IFN-γ, and MHC-class II expression in host mice were indispensable for the antitumor activity initiated by effector CD4(+) T cells. Despite comparable suppressive activity of IL-6(+/+) and IL-6(-/-) MDSC on primary T-cell activation, transfer of IL-6(+/+) MDSC, but not IL-6(-/-) MDSC, dampened the efficient induction of effector TH1 cells and counteracted CD4(+) T cell-mediated antitumor immunity including cognate help for CD8(+) T cells in vivo. These findings suggest that, apart from the inhibitory effects on primary T-cell activation, MDSC promote tumor progression by attenuating functional differentiation of tumor-specific CD4(+) T cells into effector TH1 cells through IL-6 production to promote tumor progression. This novel mode of MDSC-induced tolerance of effector CD4(+) T cells should be considered as the basis for the rational design of effective T cell-mediated antitumor therapies. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24777249     DOI: 10.1158/2326-6066.CIR-13-0030

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  33 in total

1.  Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity.

Authors:  Yi Ban; Junhua Mai; Xin Li; Marisa Mitchell-Flack; Tuo Zhang; Lixing Zhang; Lotfi Chouchane; Mauro Ferrari; Haifa Shen; Xiaojing Ma
Journal:  Cancer Res       Date:  2017-04-17       Impact factor: 12.701

2.  Granulocytic myeloid-derived suppressor cells from human cord blood modulate T-helper cell response towards an anti-inflammatory phenotype.

Authors:  Natascha Köstlin; Margit Vogelmann; Bärbel Spring; Julian Schwarz; Judith Feucht; Christoph Härtel; Thorsten W Orlikowsky; Christian F Poets; Christian Gille
Journal:  Immunology       Date:  2017-06-08       Impact factor: 7.397

3.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

Authors:  Thomas A Mace; Reena Shakya; Jason R Pitarresi; Benjamin Swanson; Christopher W McQuinn; Shannon Loftus; Emily Nordquist; Zobeida Cruz-Monserrate; Lianbo Yu; Gregory Young; Xiaoling Zhong; Teresa A Zimmers; Michael C Ostrowski; Thomas Ludwig; Mark Bloomston; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Gut       Date:  2016-10-21       Impact factor: 23.059

Review 4.  Environmental immune disruptors, inflammation and cancer risk.

Authors:  Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

5.  Curcumin up regulates T helper 1 cells in patients with colon cancer.

Authors:  Bin Xu; Lin Yu; Li-Zhong Zhao
Journal:  Am J Transl Res       Date:  2017-04-15       Impact factor: 4.060

Review 6.  Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.

Authors:  Douglas Marvel; Dmitry I Gabrilovich
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

7.  Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Authors:  Daniel W Beury; Katherine H Parker; Maeva Nyandjo; Pratima Sinha; Kayla A Carter; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2014-08-28       Impact factor: 4.962

8.  IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients.

Authors:  Ahmed-Amine Zergoun; Abderezak Zebboudj; Sarah Leila Sellam; Nora Kariche; Djamel Djennaoui; Samir Ouraghi; Esma Kerboua; Zine-Charaf Amir-Tidadini; Dalia Chilla; Fatima Asselah; Chafia Touil-Boukoffa; Taha Merghoub; Mehdi Bourouba
Journal:  Tumour Biol       Date:  2015-10-09

9.  CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis.

Authors:  Hiroshi Katoh; Dingzhi Wang; Takiko Daikoku; Haiyan Sun; Sudhansu K Dey; Raymond N Dubois
Journal:  Cancer Cell       Date:  2013-11-11       Impact factor: 31.743

10.  IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age.

Authors:  Hirotake Tsukamoto; Satoru Senju; Keiko Matsumura; Susan L Swain; Yasuharu Nishimura
Journal:  Nat Commun       Date:  2015-04-07       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.